ArticleCardiology2026
Study Design of the Akershus Cardiac Examination (ACE) 4 Study: Pragmatic Randomized Controlled Trial Assessing the Effect of Early Biomarker Measurements and Structured Feedback in Unselected Patients Hospitalized with Tachypnea.
Article in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with acute tachypnea pose diagnostic challenges in the emergency department (ED). Biomarkers such as N-terminal pro-B-type natriuretic peptide and cardiac troponin T improve diagnostic accuracy and risk stratification in patients with cardiovascular disease but may not be optimally assessed by clinicians in the ED. The aim of the Akershus Cardiac Examination 4 (ACE 4) study is to test whether early biomarker measurements with structured feedback in patients' electronic health records using a predetermined biomarker algorithm improve clinical outcomes in unselected patients hospitalized with tachypnea compared to standard care. The primary outcome is time to mortality or rehospitalization.
methodsThe ACE 4 study is a single-center, pragmatic, non-pharmacological, randomized clinical trial including patients with acute tachypnea within 24 h of hospitalization. Patients will be randomized to either early biomarker measurements and feedback in the patient electronic medical health record using a predefined biomarker-based algorithm to assess the risk of heart failure (intervention group) or biomarker measurements without structured feedback (control group). We will preregister the study protocol and statistical analysis plan, and we will monitor data extraction and study execution.
conclusionWe hypothesize that early biomarker measurements and structured feedback in the patients' electronic health records using a predetermined biomarker algorithm will improve clinical outcomes in patients hospitalized with tachypnea compared to the standard of care. We will test this hypothesis in the ACE 4 study using a pragmatic, electronic health record-randomized controlled design, which enables inclusion of large patient groups in daily clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.